PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.50
D/E of 0.50 versus zero Medical - Pharmaceuticals median. Walter Schloss would verify if our leverage provides competitive advantages.
-1.53
Net cash position versus Medical - Pharmaceuticals median net debt of 1.72. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
46.19
Coverage of 46.19 versus zero Medical - Pharmaceuticals median interest expense. Walter Schloss would verify if our leverage provides advantages.
0.90
Current ratio 50-75% of Medical - Pharmaceuticals median of 1.57. Martin Whitman would look for hidden assets or working capital optimization.
0.66%
Intangibles 1.25-1.5x Medical - Pharmaceuticals median of 0.50%. Martin Whitman would scrutinize acquisition strategy and impairment risks.